The acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary suite of genomic technologies and services
The acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary suite of genomic technologies and services
RECOMMENDED CASH OFFER by Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.) for Yourgene Health plc to be effected by means of a Scheme of Arrangement under Part
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation
A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children
Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation
Trading update and progress against strategy for H1 2022
Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with